{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"title":"Not evaluable"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Without CRAB"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"defined as the time from random assignment to the early or late strategy to the date of onset of CRAB symptoms or death.\n\nClinical relapse requires one or more direct indicators of progressive disease and end organ dysfunction (CRAB features). Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder:\n\n* hypercalcaemia\n* renal insufficiency\n* anaemia\n* bone lesions\n\nAny one or more of the following biomarkers of malignancy:\n\n* clonal bone marrow plasma cell percentage ≥60%\n* involved:uninvolved serum free light chain ratio ≥100\n* \\>1 focal lesions on MRI studies (each focal lesion must be 5 mm or more in size)\n\nProgresson was defined accoring to IMWG criteria as reported before","groups":[{"description":"Early Treatment","id":"OG000","title":"Arm I"},{"description":"Late treatment","id":"OG001","title":"Arm II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All population","reportingStatus":"POSTED","timeFrame":"57 months","title":"Clinical Progression","type":"SECONDARY","unitOfMeasure":"Participants"}